Skip to main content
. 2010 Apr 21;16(15):1896–1900. doi: 10.3748/wjg.v16.i15.1896

Table 1.

Clinical characteristics of patients taking LDA enrolled in the present study

Patients with ulcer (n = 119) Patients without ulcer (n = 334) P-value
Gender (male/female) 87/32 211/123 NS
Age (yr), median (range) 73.0 (47-92) 72.0 (45-95) NS
Male (n = 298) 70.0 (47-92) 71.0 (43-93) NS
Female (n = 155) 77.0 (54-92) 73.0 (47-95) 0.0338
Underlying disease (male/female)
Ischemic heart disease 77 (61/16) 205 (131/74) NS
Cerebral infarction 22 (10/12) 70 (39/31) NS
Atrial fibrillation 16 (13/3) 43 (28/15) NS
Others 4 (3/1) 16 (13/3) NS
Symptoms (male/female)
Melena, hematemesis 46 (29/17) 1 (0/1) < 0.0001
GI symptoms 31 (21/10) 107 (72/35) NS1
Anemia 17 (14/3) 40 (21/19) 0.0156
Body weight loss 1 (1/0) 7 (5/2) 0.0087
Appetite loss 1 (1/0) 8 (2/6) 0.0028
None (medical check) 18 (15/3) 146 (96/50) 0.0025
Others 5 (2/0) 25 (15/10) > 0.9999
Helicobacter pylori 62.3% (43/69) -
Male 66.7% (30/45) -
Female 54.2% (13/24) -
1

Forty-six patients presented with melena and/or hematemesis and bleeding source in the stomach or duodenum identified by endoscopy and were excluded from GI symptoms in this analysis. LDA: Low-dose aspirin; GI: Gastrointestinal; NS: Not significant.